Parp inhibitors as indicated on our homepage are drugs which are cancer growth inhibitors. There are two different drugs being trialed currently which will hopefully pass the parp inhibitor trials and be available as an anti-cancer drug.
Parp Inhibitors are inhibitors for cancer treatment and the parp-1 inhibitor trials have shown that 63% had tumor responses which were positive and led to disease stabilization for at least four months, these responses were sustained for 52-76 weeks so these are very positive results. Whilst these drug trials are still preliminary, Dr Eric Winer, a breast cancer chief is excited by the results.
A Parp Inhibitor is also useful as it can be used as enzyme inhibitors in cancers that are very aggressive where there are no current treatments beyond chemotherapy. In one parp inhibitor trial of the BiPar Sciences BSI 201 drug tumors shrank in half of the patients treated compared with just 16% of patients on chemotherapy alone, side effects were also similar for both groups showing parp-1 inhibitors to have no known side effects.
These parp inhibitors were first created in 2005 when Professor Alan Ashworth, Dr Andrew Tutt and colleagues at the Breakthrough research center published work showing that cells with the faulty BRCA genes are highly sensitive to parp-inhibitors. The BRCA1 and BRCA2 genes are important for the repair of DNA and when this function is lost cells are unable to repair the damage to their DNA which makes the individual a higher risk for having breast cancer or ovarian cancer. Scientists have found that the parp enzyme is particularly sensitive to the inhibition of parp enzymatic activity, this results in the cancer tumor cells being unable to grow.